Tg Therapeutics, Inc. (TGTX)
| Market Cap | 8.02B+46.6% |
| Revenue (ttm) | 799.54M |
| Net Income | 441.49M |
| EPS | 2.75 |
| Shares Out | 153.08M |
| PE Ratio | 19.05 |
| Forward PE | 19.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 252,064 |
| Open | 53.34 |
| Previous Close | 52.95 |
| Day's Range | 52.12 - 53.34 |
| 52-Week Range | 26.76 - 59.30 |
| Beta | 1.80 |
| Analysts | Strong Buy |
| Price Target | 69.71(+33.04%) |
| Earnings Date | Nov 2, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TGTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TGTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TGTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TGTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New TGTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TGTX from public contracts
Source: USAspending.gov
TGTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TGTX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score